for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Athersys, Inc.

ATHX.OQ

Latest Trade

1.44USD

Change

-0.01(-0.69%)

Volume

403,972

Today's Range

1.40

 - 

1.45

52 Week Range

1.20

 - 

2.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.45
Open
1.44
Volume
403,972
3M AVG Volume
12.14
Today's High
1.45
Today's Low
1.40
52 Week High
2.23
52 Week Low
1.20
Shares Out (MIL)
152.68
Market Cap (MIL)
221.38
Forward P/E
-4.03
Dividend (Yield %)
--

Next Event

Q3 2019 Athersys Inc Earnings Release

Latest Developments

More

Athersys Q2 Loss Per Share $0.06

Athersys Inc Enters Open Market Sale Agreement With Jefferies LLC To Offer And Sell Shares Up To $50.0 Million

Athersys Reports Q1 Loss Per Share $0.09

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Athersys, Inc.

Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Industry

Biotechnology & Drugs

Contact Info

3201 Carnegie Ave

+1.216.4319900

http://www.athersys.com/

Executive Leadership

Gil Van Bokkelen

Chairman of the Board, Chief Executive Officer

William B.J. Lehmann

President, Chief Operating Officer

John J. Harrington

Executive Vice President, Chief Scientific Officer, Director

Laura K. Campbell

Senior Vice President - Finance

Lee E. Babiss

Lead Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.180

2017

-0.290

2018

-0.180

2019(E)

-0.330
Price To Earnings (TTM)
--
Price To Sales (TTM)
23.20
Price To Book (MRQ)
6.62
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-90.30
Return on Equity (TTM)
-69.29

Latest News

BRIEF-Athersys And Healios Extend By One Month The Period To Complete Collaboration Expansion Agreements

* ATHERSYS AND HEALIOS EXTEND BY ONE MONTH THE PERIOD TO COMPLETE COLLABORATION EXPANSION AGREEMENTS

BRIEF-Uthealth In Houston And Athersys Announce Funding For Clinical Trial Using Multistem® To Treat Trauma Patients

* UTHEALTH IN HOUSTON AND ATHERSYS ANNOUNCE FUNDING FOR CLINICAL TRIAL USING MULTISTEM® TO TREAT TRAUMA PATIENTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Healios K.K. Reports 8.7 Pct Stake In Athersys

* HEALIOS K.K. REPORTS 8.7 PERCENT STAKE IN ATHERSYS INC AS OF MARCH 13, 2018 - SEC FILING Source text: (https://bit.ly/2G0glmi)

BRIEF-Athersys Reports Q4 Revenue $1.2 Million Versus $1.0 Million

* ATHERSYS REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER, FULL YEAR 2017

BRIEF-Athersys Inc Files Prospectus Relates Potential Sale Of Up To 24.7 mln Shares Of Co's Common Stock By Aspire Capital

* ATHERSYS INC FILES PROSPECTUS RELATES POTENTIAL SALE OF UP TO 24.7 MILLION SHARES OF CO'S COMMON STOCK BY ASPIRE CAPITAL - SEC FILING Source text - (http://bit.ly/2nyf89E) Further company coverage:

BRIEF-Athersys Enters Into New $100 Mln Equity Facility With Aspire Capital

* ATHERSYS ENTERS INTO NEW $100 MILLION EQUITY FACILITY WITH ASPIRE CAPITAL

BRIEF-Athersys Says On Feb 1, Co Entered Into Common Stock Purchase Agreement With Aspire Capital Fund

* ATHERSYS INC SAYS ON FEB 1, CO ENTERED INTO COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND - SEC FILING

BRIEF-Athersys reports Q3 loss per share $0.06

* Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Athersys enters agreement with Garnet to settle intellectual property disagreements

* Athersys says on Oct 12, co entered into agreement with Garnet to settle intellectual property disagreements between parties - SEC filing Source text: (http://bit.ly/2zcHTNn) Further company coverage:

BRIEF-Athersys and Nikon Cell Innovation to collaborate on MultiStem manufacturing in Japan

* Athersys and Nikon Cell Innovation to collaborate on multistem commercial manufacturing in Japan

BRIEF-Athersys Q2 loss per share $0.06

* Q2 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Athersys reports alignment of key regulators for pivotal registration study in stroke

* Athersys reports alignment of key regulators for pivotal registration study in stroke

BRIEF-Athersys reports Q1 loss per share $0.06

* Q1 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Athersys Inc files for mixed shelf offering of up to $75 mln

* Athersys Inc files for mixed shelf offering of up to $75 million - sec filing Source text (http://bit.ly/2lMjdJc) Further company coverage:

BRIEF-Athersys reports pricing of public offering of common stock

* Athersys announces pricing of public offering of common stock Source text for Eikon: Further company coverage:

BRIEF-Athersys announces proposed public offering of common stock

* Intends to offer for sale shares of its common stock, par value $0.001 per share

BRIEF-Athersys reports Q3 loss per share $0.07

* Q3 loss per share $0.07 Source text for Eikon: Further company coverage:

BRIEF-Athersys, FDA agree on design for ischemic stroke late-stage study

* Athersys receives FDA agreement under special protocol assessment for phase 3 study of multistem treatment for ischemic stroke Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up